News and Reports
-
Harmony Biosciences Secures $200 Million Debt Facility
27 January 2020Download -
Neurelis announces FDA approval for seizure rescue treatment VALTOCO®
13 January 2020Download -
Arcutis Announces ARQ-154 Program for Seborrheic Dermatitis and Enrollment of First Patient in Phase 2 Proof of Concept Clinical Trial
5 December 2019Download -
Arcutis Biotherapeutics Announces Positive End-of-Phase 2 Meeting with FDA and Planned Initiation of Phase 3 Program for ARQ-151 for Plaque Psoriasis
24 October 2019Download -
Arcutis Announces the Completion of $94.5 million Series C Financing
21 October 2019Download -
UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases
10 October 2019Download -
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares
7 October 2019Download -
Swixx signs deal to represent Alexion in Russia & announces opening of Russian operations and Swixx appointed distributor for Alexion Russia
1 October 2019Download -
Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock
26 September 2019Download -
U.S. FDA accepts for review Viela Bio's first BLA filing
27 August 2019Download -
Harmony Biosciences Announces FDA Approval of WAKIX (pitolisant), a First-In-Class Medication for the Treatment of Excessive Daytime Sleepiness in Adult Patients with Narcolepsy
15 August 2019Download -
SpringWorks Therapeutics Announces Global Clinical Collaboration with GlaxoSmithKline to Evaluate Nirogacestat in Combination with Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma
27 June 2019Download -
1mg to accelerate investments in Growth, Supply Chain & AI/ML driven personalized care
27 June 2019Download -
Viela Bio Closes $75 Million Series B Financing
17 June 2019Download -
Corvidia Therapeutics Initiates Phase 2b Dose-Finding Study for Ziltivekimab
13 June 2019Download -
SpringWorks Therapeutics Announces FDA Fast Track Designation for PD-0325901 for the Treatment of a Severe Form of Neurofibromatosis Type 1
3 June 2019Download -
Forbius: First Patient Dosed in a Phase 1b Myelofibrosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
24 April 2019Download -
Arrakis Therapeutics Raises $75M Series B To Develop Small-Molecule Medicines Targeting RNA
18 April 2019Download -
HOOKIPA Pharma Announces Pricing of Initial Public Offering
17 April 2019Download -
SpringWorks Therapeutics Completes $125 Million Series B Financing
1 April 2019Download -
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
29 March 2019Download -
HOOKIPA PROPOSES IPO AS ITS CANCER VACCINES HEAD TOWARDS THE CLINIC
22 March 2019Download -
Adrenomed’s Adrecizumab successfully passes interim analysis in early septic shock study AdrenOSS-II
21 March 2019Download -
Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor
4 March 2019Download -
Principia Biopharma Announces Positive Data from Phase 2 Pemphigus Vulgaris Trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation
2 March 2019Download